Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network

Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network

Decitabine, a DNA hypomethylating agent, was approved for use in adults with acute myeloid leukemia (AML) not eligible for standard chemotherapy and is now widely accepted as standard treatment. Although a number of clinical trials demonstrated its benefits in elderly AML patients, older adults and...

Full description

Bibliographic Details
Main Authors: Michelina Dargenio, Giuseppe Tarantini, Nicola Cascavilla, Enzo Pavone, Pellegrino Musto, Patrizio Mazza, Lorella Melillo, Domenico Pastore, Attilio Guarini, Caterina Buquicchio, Maria Paola Fina, Vincenzo Federico, Teresa Maria Santeramo, Marina Aurora Urbano, Mariangela Leo, Vera Carluccio, Paola Carluccio, Mario Delia, Daniela Carlino, Carolina Vergine, Vito Pier Gagliardi, Giuseppina Greco, Silvia Sibilla, Mariachiara Abbenante, Giovanni Rossi, Giuseppina Spinosa, Annamaria Mazzone, Lara Aprile, Vincenza de Fazio, Crescenza Pasciolla, Giorgina Specchia, Nicola Di Renzo
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
acute myeloid leukemia
decitabine
elderly
real-world study
treatment
Online Access:https://www.mdpi.com/2072-6694/14/3/826

Similar Items

Similar Items